← Research library

Peptide bioregulators: delivery and efficacy

Comparison in people · 2020

What was studied
Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
Main finding
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.

Group I total retinal-sensitivity change, initial/moderate/advanced disease · +122 / +166 / +124 dB · Month 3

Reported findings and study design

498 glaucoma patients/eyes as printed; group I combined IM/retrobulbar 110, group II retrobulbar 171, group III IM (count not explicitly printed). Retinalamin 5 mg per stated route; total course 50 mg. Assessments months 3 and 6.

Population or model Open-angle glaucoma; 498 patients (eyes), as worded in the abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Group I total retinal-sensitivity change, initial/moderate/advanced disease+122 / +166 / +124 dBMonth 3
Group II, initial/moderate disease+123 / +110 dBAdvanced disease: no significant change
Group III, initial/moderate/advanced disease+142 / +274 / +148 dB
DurabilityRegression described from month 6 in group III
Visual acuityNo significant change

These large dB totals sum threshold values across visual-field locations; they are not a single-point sensitivity increase. Patient/eye terminology is ambiguous in the abstract.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • All compared groups received active preparation; this does not isolate benefit versus no Retinalamin.
  • Patient/eye unit wording should be checked in full text. Findings do not establish benefit for Normophthal.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

Human comparative studyEnglish abstract

Erichev VP, Lovpache DN, Yaremenko TV. Peptide bioregulators: delivery and efficacy Vestn Oftalmol 136(2):56-62. PMID 32366071

Study source ↗ · DOI 10.17116/oftalma202013602156 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards